Your browser doesn't support javascript.
loading
CMV seroprevalence and coronary CMV-DNA detection in immunocompetent patients with heart diseases.
Cento, Valeria; Colagrossi, Luna; Bossi, Irene; Armenia, Daniele; Nava, Alice; Piccinelli, Enrico; Maloberti, Alessandro; Inglese, Elvira; Matarazzo, Elisa; DI Ruscio, Federica; Paba, Pierpaolo; Marcuccilli, Fabbio; Perrone, Marco; Chiricolo, Gaetano; Alteri, Claudia; Scaglione, Francesco; Vismara, Chiara; Campisi, Daniela A; Fanti, Diana; Romeo, Francesco; Andreoni, Massimo; Oliva, Fabrizio; Ceccherini-Silberstein, Francesca; Giannattasio, Cristina; Perno, Carlo F.
Afiliação
  • Cento V; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy - valeria.cento@unimi.it.
  • Colagrossi L; Unit of Microbiology and Diagnostic Immunology, Bambino Gesù Children's Hospital, Rome, Italy.
  • Bossi I; A. De Gasperis Cardio Center, ASST Niguarda Hospital, Milan, Italy.
  • Armenia D; Saint Camillus International University of Health Sciences, UniCamillus, Rome, Italy.
  • Nava A; Unit of Chemical-Clinical and Microbiological Analysis, ASST Niguarda Hospital, Milan, Italy.
  • Piccinelli E; A. De Gasperis Cardio Center, ASST Niguarda Hospital, Milan, Italy.
  • Maloberti A; A. De Gasperis Cardio Center, ASST Niguarda Hospital, Milan, Italy.
  • Inglese E; Unit of Chemical-Clinical and Microbiological Analysis, ASST Niguarda Hospital, Milan, Italy.
  • Matarazzo E; Residency in Microbiology and Virology, University of Milan, Milan, Italy.
  • DI Ruscio F; Residency in Microbiology and Virology, University of Milan, Milan, Italy.
  • Paba P; Unit of Virology, Tor Vergata Polyclinic Foundation, Tor Vergata University, Rome, Italy.
  • Marcuccilli F; Unit of Virology, Tor Vergata Polyclinic Foundation, Tor Vergata University, Rome, Italy.
  • Perrone M; Unit of Cardiology, Tor Vergata Polyclinic Foundation, Tor Vergata University, Rome, Italy.
  • Chiricolo G; Unit of Cardiology, Tor Vergata Polyclinic Foundation, Tor Vergata University, Rome, Italy.
  • Alteri C; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
  • Scaglione F; Unit of Chemical-Clinical and Microbiological Analysis, ASST Niguarda Hospital, Milan, Italy.
  • Vismara C; Unit of Chemical-Clinical and Microbiological Analysis, ASST Niguarda Hospital, Milan, Italy.
  • Campisi DA; Unit of Chemical-Clinical and Microbiological Analysis, ASST Niguarda Hospital, Milan, Italy.
  • Fanti D; Unit of Chemical-Clinical and Microbiological Analysis, ASST Niguarda Hospital, Milan, Italy.
  • Romeo F; Unit of Cardiology, Tor Vergata Polyclinic Foundation, Tor Vergata University, Rome, Italy.
  • Andreoni M; Unit of Infectious Diseases, Tor Vergata Polyclinic Foundation, Tor Vergata University, Rome, Italy.
  • Oliva F; A. De Gasperis Cardio Center, ASST Niguarda Hospital, Milan, Italy.
  • Ceccherini-Silberstein F; Department of Experimental Medicine, Tor Vergata University, Rome, Italy.
  • Giannattasio C; A. De Gasperis Cardio Center, ASST Niguarda Hospital, Milan, Italy.
  • Perno CF; Unit of Microbiology and Diagnostic Immunology, Bambino Gesù Children's Hospital, Rome, Italy.
Minerva Med ; 114(3): 289-299, 2023 Jun.
Article em En | MEDLINE | ID: mdl-36255708
ABSTRACT

BACKGROUND:

Acute coronary syndromes (ACS) are a major cause of morbidity and mortality. As cytomegalovirus (CMV) may contribute to cardio-vascular (CV) manifestations, we sought to provide a proof-of-concept for the involvement of coronary and/or systemic CMV-reactivation as a possible ACS trigger.

METHODS:

We prospectively enrolled consecutive patients undergoing a coronary angiography for ACS (acute-cases, N.=136), or non-ACS reasons (chronic-cases, N.=57). Matched coronary and peripheral blood-samples were processed for quantification of CMV-DNAemia (RT-PCR), CMV-IgG/IgM, and CMV-IgG avidity (ELISA). Peripheral-blood samples from 17 healthy subjects were included as controls.

RESULTS:

Out of the 193 cases included, 18.1% were aged ≤55 years, 92.5% were Central-European, and 100% immunocompetent. CMV-IgG seroprevalence was 91.7% (95%CI 87.8-95.6), significantly higher than in healthy-controls (52.9% [95%CI 29.2-76.5]; P<0.001), yet consistent across age-groups (P=0.602), male/females (P=0.765), and acute/chronic-cases (P=0.157). Median (IQR) IgG titers were 110 (84-163) AU/mL, with 0.62 (0.52-0.72) avidity, supporting a long history of infection. No acute CMV infections were found. In 22.6% (n/N.=40/177) of the IgG-positive cases low-level coronary and/or systemic CMV-DNAemia (always <40 copies/mL) was detected. While no differences in peripheral CMV-DNAemia prevalence were observed nor among cases nor controls, coronary CMV-DNAemia was more frequent in acute-cases without modifiable CV risk-factors (n/N.=4/10; 40.0%), than in chronic-cases (n/N.=6/55, 10.9%; P=0.029), or acute-cases with risk-factors (n/N.=16/112, 14.3%; P=0.058).

CONCLUSIONS:

CMV-IgG seroprevalence was high in patients with heart diseases. CMV-DNAemia can be found, although uncommonly, in coronary circulation during an ACS, with increased prevalence in older subjects and in absence of CV risk-factors, identifying possible areas for novel interventions.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções por Citomegalovirus / Síndrome Coronariana Aguda Tipo de estudo: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções por Citomegalovirus / Síndrome Coronariana Aguda Tipo de estudo: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male Idioma: En Ano de publicação: 2023 Tipo de documento: Article